Database Analysis of Eplerenone Use in Japanese Hypertensive Patients in Clinical Practice
Eplerenone, a mineralocorticoid receptor antagonist (MRA), is available in Japan, but details of its use in clinical settings have not been thoroughly investigated. Thus, this study was aimed at examining the characteristics of eplerenone-prescribed hypertensive patients in Japan, describing the com...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.1155/2019/3726419 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551997051502592 |
|---|---|
| author | Shoko Takahashi Yoichi Ii Yuji Yamamoto Aya Ikeda Yoko Fujimoto |
| author_facet | Shoko Takahashi Yoichi Ii Yuji Yamamoto Aya Ikeda Yoko Fujimoto |
| author_sort | Shoko Takahashi |
| collection | DOAJ |
| description | Eplerenone, a mineralocorticoid receptor antagonist (MRA), is available in Japan, but details of its use in clinical settings have not been thoroughly investigated. Thus, this study was aimed at examining the characteristics of eplerenone-prescribed hypertensive patients in Japan, describing the combination patterns of antihypertensive medications, and comparing eplerenone’s mean doses with respect to concomitant diseases. Data of 160,992 hypertensive patients who used the same drugs for six months or more were collected from an insurance database from January 1, 2009, to December 31, 2013. The number of MRA-receiving patients among the extracted population was 3,274 (2%). Compared to patients on eplerenone or spironolactone, patients on neither drug had fewer comorbidities. Eplerenone was administered in combination with calcium channel blockers and angiotensin II receptor blockers in 23.1% and as monotherapy in 6.6% of cases. The most frequent initial daily dose of eplerenone was 50 mg/day followed by 25 mg/day irrespective of the presence of a comorbidity. MRA use was as low as 2%, but its use was more frequent in patients with comorbidities compared to that of other antihypertensives. Despite studies showing eplerenone’s efficacy and safety in high-risk hypertensive patients with albuminuria, the drug is not widely used. |
| format | Article |
| id | doaj-art-1799be1dd41f41b78303e7041a0c9846 |
| institution | Kabale University |
| issn | 2090-0384 2090-0392 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-1799be1dd41f41b78303e7041a0c98462025-02-03T05:59:51ZengWileyInternational Journal of Hypertension2090-03842090-03922019-01-01201910.1155/2019/37264193726419Database Analysis of Eplerenone Use in Japanese Hypertensive Patients in Clinical PracticeShoko Takahashi0Yoichi Ii1Yuji Yamamoto2Aya Ikeda3Yoko Fujimoto4Internal Medicine Medical Affairs, Pfizer Japan Inc., 3-22-7 Yoyogi, Shibuya-ku, Tokyo 151-8589, JapanClinical Statistics, Development Japan, Pfizer Japan Inc., 3-22-7 Yoyogi, Shibuya-ku, Tokyo 151-8589, JapanMinaCare Co., Ltd., 5F 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-0023, JapanMinaCare Co., Ltd., 5F 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-0023, JapanUpjohn Medical Affairs, Pfizer Japan Inc., 3-22-7 Yoyogi, Shibuya-ku, Tokyo 151-8589, JapanEplerenone, a mineralocorticoid receptor antagonist (MRA), is available in Japan, but details of its use in clinical settings have not been thoroughly investigated. Thus, this study was aimed at examining the characteristics of eplerenone-prescribed hypertensive patients in Japan, describing the combination patterns of antihypertensive medications, and comparing eplerenone’s mean doses with respect to concomitant diseases. Data of 160,992 hypertensive patients who used the same drugs for six months or more were collected from an insurance database from January 1, 2009, to December 31, 2013. The number of MRA-receiving patients among the extracted population was 3,274 (2%). Compared to patients on eplerenone or spironolactone, patients on neither drug had fewer comorbidities. Eplerenone was administered in combination with calcium channel blockers and angiotensin II receptor blockers in 23.1% and as monotherapy in 6.6% of cases. The most frequent initial daily dose of eplerenone was 50 mg/day followed by 25 mg/day irrespective of the presence of a comorbidity. MRA use was as low as 2%, but its use was more frequent in patients with comorbidities compared to that of other antihypertensives. Despite studies showing eplerenone’s efficacy and safety in high-risk hypertensive patients with albuminuria, the drug is not widely used.http://dx.doi.org/10.1155/2019/3726419 |
| spellingShingle | Shoko Takahashi Yoichi Ii Yuji Yamamoto Aya Ikeda Yoko Fujimoto Database Analysis of Eplerenone Use in Japanese Hypertensive Patients in Clinical Practice International Journal of Hypertension |
| title | Database Analysis of Eplerenone Use in Japanese Hypertensive Patients in Clinical Practice |
| title_full | Database Analysis of Eplerenone Use in Japanese Hypertensive Patients in Clinical Practice |
| title_fullStr | Database Analysis of Eplerenone Use in Japanese Hypertensive Patients in Clinical Practice |
| title_full_unstemmed | Database Analysis of Eplerenone Use in Japanese Hypertensive Patients in Clinical Practice |
| title_short | Database Analysis of Eplerenone Use in Japanese Hypertensive Patients in Clinical Practice |
| title_sort | database analysis of eplerenone use in japanese hypertensive patients in clinical practice |
| url | http://dx.doi.org/10.1155/2019/3726419 |
| work_keys_str_mv | AT shokotakahashi databaseanalysisofeplerenoneuseinjapanesehypertensivepatientsinclinicalpractice AT yoichiii databaseanalysisofeplerenoneuseinjapanesehypertensivepatientsinclinicalpractice AT yujiyamamoto databaseanalysisofeplerenoneuseinjapanesehypertensivepatientsinclinicalpractice AT ayaikeda databaseanalysisofeplerenoneuseinjapanesehypertensivepatientsinclinicalpractice AT yokofujimoto databaseanalysisofeplerenoneuseinjapanesehypertensivepatientsinclinicalpractice |